Abstract:Immune checkpoints are crucial molecules for the maintenance of antitumor immune responses. The activation or inhibition of these molecules is dependent on the interactions between receptors and ligands; such interactions can provide inhibitory or stimulatory signals to the various components of the immune system. Over the last 10 years, the inhibition of immune checkpoints, such as cytotoxic T lymphocyte antigen-4, programmed cell death-1, and programmed cell death ligand-1, has taken a leading role in immune therapy. This relatively recent therapy regime is based on the use of checkpoint inhibitors, which enhance the immune response towards various forms of cancer. For a subset of patients with specific forms of cancer, these inhibitors can induce a durable response to therapy; however, the medium response rate to such therapy remains relatively poor. Recent research activities have demonstrated that the disease response to this highly promising therapy resembles the response of many forms of cancer to chemotherapy, where an encouraging initial response is followed by acquired resistance to treatment and progress of the disease. That said, these inhibitors are now used as single agents or in combination with chemotherapies as first or second lines of treatment for about 50 types of cancer. The prevailing opinion regarding immune therapy suggests that for this approach of therapy to deliver on its promise, a number of challenges have to be circumvented. These challenges include understanding the resistance mechanisms to immune checkpoint blockade, the identification of more efficient inhibitors, extending their therapeutic benefits to a wider audience of cancer patients, better management of immune-related adverse side effects, and, more urgently the identification of biomarkers, which would help treating oncologists in the identification of patients who are likely to respond positively to the immune therapies and, last but not least, the prices of therapy which can be afforded by the highest number of patients. Numerous studies have demonstrated that understanding the interaction between these checkpoints and the immune system is essential for the development of efficient checkpoint inhibitors and improved immune therapies. In the present text, we discuss some of these checkpoints, their inhibitors, and some works in which mass spectrometry-based proteomic analyses were applied.

Checkpoints under Traffic Control: from and to Organelles

[Tracking Research Progress in the Modulatory Role of Gut Microbiome in Immune Checkpoint Inhibitors Applied in Cancer Treatment].

The Nuclear Transportation of PD-L1 and the Function in Tumor Immunity and Progression

Tumor Immune Checkpoints and Their Associated Inhibitors

Unleashing the power of immune checkpoints: Post-translational modification of novel molecules and clinical applications

Immune checkpoint: The novel target for antitumor therapy

[Next generation of anti-immune checkpoints antibodies]

Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4

Lipid Metabolism and Immune Checkpoints.

Soluble immune checkpoints in cancer: production, function and biological significance

Proteomic Investigation of Immune Checkpoints and Some of Their Inhibitors

Glycosylation and Its Role in Immune Checkpoint Proteins: From Molecular Mechanisms to Clinical Implications

Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer

Immune checkpoint signaling and cancer immunotherapy

Current Progress and Future Perspectives of Immune Checkpoint in Cancer and Infectious Diseases

Structures of Immune Checkpoints: An Overview on the CD28-B7 Family.

Functions of Immune Checkpoint Molecules Beyond Immune Evasion

Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts

The TSP1-CD47-SIRPα interactome: an immune triangle for the checkpoint era

Targeting the ubiquitination/deubiquitination process to regulate immune checkpoint pathways

Emerging immune checkpoints for cancer therapy